Incretin-Based Treatment

PreclinicalSmall molecule

Incretin-Based Treatment is one of 22 small molecule programs targeting Physical Activity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Physical ActivityActive, not recruiting

Obesity & OverweightRecruiting

Physical ActivityPreclinical

Active, not recruiting

Obesity & OverweightPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Physical Activity

#DrugCompanyPhaseTrials

Xolair

Roche

Approved

1 2

Hemlibra

Roche

Approved

—3

Ranexa

MMenarini International Operations Luxembourg SA

Approved

1 4

Taxol

Teva

Preclinical

1 5

Nicorette

Pfizer

Preclinical

1 6

Anamorelin Hydrochloride

MM.D. Anderson Cancer Center

Phase 2

1 7

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Efanesoctocog Alfa

Sanofi

Preclinical

1 9

Immunotherapy

Bristol-Myers Squibb

Preclinical

—10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Obesity & Overweight

NCT07409831

Clinical

Trials by Indication[1]

Trial1 trial

Glycemia in Diabetic Elders Trial

Terminated·JJohns Hopkins University·Phase 4·NCT02029846·2 enrolled

Obesity & Overweight1 trial

Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle

Recruiting·LLaval University·Preclinical·NCT07409831·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Incretin-Based Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Incretin-Based Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Incretin-Based Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJohns Hopkins University

Incretin-Based Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Trial1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News